Initial Therapy of Advanced Anaplastic Thyroid Cancer via Targeting VEGFR-2: A Case Report

• Main Authors: Cheng L, Jiao Q, Jin Y, Fu H, Zhang H, Chen L
• Format: Article
• Language: English
• Published: Dove Medical Press 2019-12-01
• Series: OncoTargets and Therapy
• Subjects: anaplastic thyroid carcinoma; vascular endothelial growth factor receptor; apatinib
• Online Access: https://www.dovepress.com/initial-therapy-of-advanced-anaplastic-thyroid-cancer-via-targeting-ve-peer-reviewed-article-OTT

Lin Cheng,1 Qiong Jiao,2 Yuchen Jin,1 Hao Fu,1 Huizhen Zhang,2 Libo Chen1 1Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China; 2Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of ChinaCorrespondence: Libo ChenDepartment of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 600 Yishan Road, Shanghai 200233, People’s Republic of ChinaTel [phone]Fax [phone]Email [e-mail]: Preclinical studies have demonstrated that Apatinib, major targeting vascular endothelial growth factor receptor-2 (VEGFR-2), could inhibit the proliferation of anaplastic thyroid carcinoma (ATC) cells in vitro and in vivo. The efficacy and safety in ATC patients, however, remains unknown. Here, we report the case of a 93-year-old female with advanced ATC who initially treated with Apatinib. The tumor shrank notably 4 weeks after the initiation of therapy, which sustained for more than 30 weeks. The cervical CT illuminated a stable disease with a best response of 19.7% of the primary lesion and shrinkage of the metastatic lymph node. Adverse events, including hypertension, dental ulcer, hand-foot syndrome, fatigue, and anorexia, were observed and lightened with supportive treatment and dose reductions. The overall survival of the patient was 41 weeks. This is the first report describing the effectiveness of the VEGFR-2 inhibitor for the treatment of advanced ATC, warranting clinical trials to further ascertain its utility in this challenging setting.Keywords: anaplastic thyroid carcinoma, vascular endothelial growth factor receptor, Apatinib